Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules

Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules

- YANO Seiji
- Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine
- NISHIOKA Yasuhiko
- Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine
- GOTO Hisatsugu
- Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine
- SONE Saburo
- Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine

References (58)
Cited by (2)

Search this Article

Author(s)

- YANO Seiji
- Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine
- NISHIOKA Yasuhiko
- Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine
- GOTO Hisatsugu
- Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine
- SONE Saburo
- Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine

Journal

Cancer Sci

Cancer Sci 94(6), 479-485, 2003-06-30

References: 58

1

<no title>

RIES LAG

SEER cancer statistics review, 1973-1998, 2001

Cited by (1)
2

Role of angiogenesis in tumor growth and metastasis

FOLKMAN J

Semin Oncol 6 Suppl 16, 15-18, 2002

Cited by (1)
3

Angiogenesis and lung cancer : potential for therapy

HERBST RS

Clin Cancer Res 6, 4604-4606, 2000

Cited by (3)
4

Expression of vascular endothelial growth factor is essential but not sufficient for production and growth of brain metastasis

YANO S

Cancer Res 60, 4959-4967, 2000

Cited by (4)
5

The seed and soil hypothesis : vascularization and brain metastases

FIDLER IJ

Lancet Oncol 3, 53-57, 2002

Cited by (1)
6

Non-small cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis

PEZZELLA F

Am J Pathol 151, 1417-1423, 1997

Cited by (2)
7

Evaluation of angiogenesis in non-small cell lung cancer : comparison between anti-CD34 antibody and anti-CD105 antibody

TANAKA F

Clin Cancer Res 7, 3410-3415, 2001

Cited by (2)
8

Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma

FONTANINI G

Clin Cancer Res 3, 861-865, 1997

Cited by (2)
9

Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer : amphiregulin and microvessel count are independent prognostic indicators of survival

FONTANINI G

Clin Cancer Res 4, 241-249, 1998

Cited by (1)
10

Expression of angiopoietins and its clinical significance in non-small cell lung cancer

TANAKA F

Cancer Res 62, 7124-7129, 2002

Cited by (2)
11

Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer

KOUKOURAKIS MI

Br J Cancer 75, 477-481, 1997

Cited by (2)
12

Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas

ACHIWA H

Clin Cancer Res 5, 1001-1005, 1999

Cited by (3)
13

Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer

YUAN A

J Clin Oncol 19, 432-441, 2001

Cited by (1)
14

Novel metastasis model of human lung cancer in SCID mice depleted of NK cells

YANO S

Int J Cancer 67, 211-217, 1996

Cited by (4)
15

Model of malignant pleural effusion of human lung adenocarcinoma in SCID mice

YANO S

Oncol Res 9, 573-579, 1997

Cited by (3)
16

Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice

MIKI T

Oncol Res 12, 209-217, 2000

Cited by (4)
17

Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer

YANAGAWA H

Cancer Immunol Immunother 48, 396-400, 1999

Cited by (3)
18

Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells

YANO S

Am J Pathol 157, 1893-1903, 2000

Cited by (3)
19

From angiogenesis to lymphangiogenesis

PLATE KH

Nat Med 7, 151-152, 2001

Cited by (3)
20

The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer

KAJITA T

Br J Cancer 85, 255-260, 2001

Cited by (2)
21

Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma

ARINAGA M

Cancer 97, 457-464, 2003

Cited by (1)
22

Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer

PASSLICK B

Clin Cancer Res 6, 3944-3948, 2000

Cited by (1)
23

Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma

HERBST RS

Clin Cancer Res 6, 790-797, 2000

Cited by (1)
24

Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines

SHIRAGA M

Cancer Res 62, 5967-5973, 2002

Cited by (2)
25

Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors

KLAPPER LN

Adv Cancer Res 77, 25-79, 2000

Cited by (3)
26

Blockade of epidermal growth factor receptor signaling in tumor cells and tumorassociated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice

KIM SJ

Clin Cancer Res 9, 1200-1210, 2003

Cited by (1)
27

ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase

HIRATA A

Cancer Res 62, 2554-2560, 2002

Cited by (5)
28

Tumor angiogenesis : Therapeutic implications

FOLKMAN J

N Engl J Med 285, 1182-1186, 1971

Cited by (10)
29

Tumor angiogenesis and accessibility : role of vascular endothelial growth factor

JAIN RK

Semin Oncol 6 Suppl 16, 3-9, 2002

Cited by (1)
30

Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation

YANO S

Clin Cancer Res 6, 957-965, 2000

Cited by (4)
31

Carboplatin (C)+Paclitaxel (T)+RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer

JOHNSON DH

Proc Am Soc Clin Oncol 20, 1256a, 2001

Cited by (1)
32

Successful long-term therapy with bevacizumab (Avastin) in solid tumors

LANGMUIR VK

Proc Am Soc Clin Oncol 21, 32a, 2002

Cited by (1)
33

A third generation matrix metalloproteinase (MMP) inhibitor (ONO4817) combined with docetaxel suppresses progression of lung-micrometastasis of MMP expressing tumor cells in nude mice

YAMAMOTO A

Int J Cancer 103, 822-828, 2003

Cited by (1)
34

A randomized double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma

FIELDING J

Proc Am Soc Clin Oncol 19, 929a, 2000

Cited by (1)
35

Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy : an NCIC-CTG and EORTC study

SHEPHERD FA

Proc Am Soc Clin Oncol 20, 11a, 2001

Cited by (1)
36

Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC)

SMYLIE M

Proc Am Soc Clin Oncol 20, 1926a, 2001

Cited by (1)
37

Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models

BLAKEY DC

Clin Cancer Res 8, 1974-1983, 2002

Cited by (2)
38

Activity of a new vascular targeting agent, ZD6126 in pulmonary metastases by human lung adenocarcinoma in nude mice

GOTO H

Cancer Res 62, 3711-3715, 2002

Cited by (4)
39

The microtubule-affecting drug paclitaxel has antiangiogenic activity

BELOTTI D

Clin Cancer Res 2, 1843-1849, 1996

Cited by (1)
40

Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumors

NEGORO S

Proc Am Soc Clin Oncol 20, 324, 1292a, 2001

Cited by (1)
41

Final results from a phase II trial of ZD1839 ("Iressa") for patients with advanced non-small-cell lung cancer (IDEAL 1)

FUKUOKA M

Proc Am Soc Clin Oncol 21, 298a, 2002

Cited by (6)
42

Bronchioloalveolar carcinoma

BARKLEY JE

J Clin Oncol 14, 2377-2386, 1996

Cited by (2)
43

A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemo-naive patients with advanced non-small cell lung cancer (INTACT 1)

GIACCONE G

Ann Oncol 13 Suppl 5, 2-3, 2002

Cited by (1)
44

ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer ; results from a phase III clinical trial (INTACT 2)

JOHNSON DH

Ann Oncol 13 Suppl 5, 127-128, 2002

Cited by (1)
45

Severe acute interstitial pneumonia and gefitinib

INOUE A

Lancet 361, 137-139, 2003

Cited by (9)
46

Clinical trials of antiangiogenic drugs : opportunities, problems, and assessment of initial results

KERBEL RS

J Clin Oncol 19 Suppl 18, 45S-51S, 2001

Cited by (1)
47

Mechanism and future directions for angiogenesis-based cancer therapies

SCAPPATICCI FA

J Clin Oncol 20, 3906-3927, 2002

DOI Cited by (5)
48

Mechanism of angiogenesis

RISAU W.

Nature 386, 671-674, 1997

Cited by (98)
49

<no title>

FONTANINI G

J. Natl. Cancer Inst. 89, 881-886, 1997

DOI Cited by (10)
50

The role of microvessel density on the survival of patients with lung cancer : a systematic review of the literature with metaanalysis

MEERT AP

Br J Cancer 87, 694-701, 2002

DOI Cited by (5)
51

Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma

BROWN P. D.

J Nati Cancer lnst 85, 574-578, 1993

DOI Cited by (25)
52

Vascular permeability factor/vascular endothelial growth factor : a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

DVORAK HF.

J Clin Oncol 20, 4368-4380, 2002

DOI Cited by (8)
53

Development of matrix metalloproteinase inhibitors in cancer therapy

HIDALGO M

J Natl Cancer Inst 93, 178-193, 2001

DOI Cited by (6)
54

The role of EGF-R expression on patient survival in lung cancer : a systematic review with meta-analysis

MEERT AP

Eur Respir J 20, 975-981, 2002

DOI Cited by (3)
55

Antiangiogenesis drugs target specific cancers, mechanisms

RANDAL J

J Natl Cancer Inst 92, 520-522, 2000

DOI Cited by (6)
56

Why the epidermal growth factor receptor? The rationale for cancer therapy

BASELGA J.

Oncologist 7 Suppl 4, 2-8, 2002

DOI Cited by (3)
57

A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa"^1)

YANO Seiji , KANEMATSU Takanori , MIKI Toyokazu , AONO Yoshinori , AZUMA Masahiko , YAMAMOTO Akihiko , UEHARA Hisanori , SONE Saburo

Cancer Sci 94(5), 453-458, 2003-05-30

Ichushi Web References (14) Cited by (8)
58

Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin

HERBST RS

J Clin Oncol 26, 3804-3814, 2002

DOI Cited by (5)

Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules

Search this Article

Author(s)

Journal

References: 58

Cited by: 2

Codes

Export